Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas

Journal of Oncology

Volumn , Issue , 2012, Pages

  Chakravarti, Arnab ^a   Shirai, Katsuyuki ^a   Siedow, Michael R ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CEDIRANIB; CILENGITIDE; DASATINIB; ERLOTINIB; IMATINIB; IRINOTECAN; LOMUSTINE; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TANDUTINIB; TEMOZOLOMIDE; THALIDOMIDE; VATALANIB;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM HEMORRHAGE; CONVULSION; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

EID: 80052674321     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/193436     Document Type: Review

References (109)

1. Wen P. Y., Kesari S., Malignant gliomas in adults The New England Journal of Medicine 2008 359 5 492 507
2. Stupp R., Mason W. P., van den Bent M. J., Weller M., Fisher B., Taphoorn M. J. B., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma The New England Journal of Medicine 2005 352 10 987 996 (Pubitemid 40349501)
3. Hegi M. E., Diserens A. C., Gorlia T., Hamou M. F., De Tribolet N., Weller M., Kros J. M., Hainfellner J. A., Mason W., Mariani L., Bromberg J. E. C., Hau P., Mirimanoff R. O., Cairncross J. G., Janzer R. C., Stupp R., MGMT gene silencing and benefit from temozolomide in glioblastoma The New England Journal of Medicine 2005 352 10 997 1003 (Pubitemid 40349502)
4. Stupp R., Hegi M. E., Mason W. P., van den Bent M. J., Taphoorn M. J., Janzer R. C., Ludwin S. K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A. A., Gijtenbeek J., Marosi C., Vecht C. J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J. G., Mirimanoff R. O., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial The Lancet Oncology 2009 10 5 459 466
5. Curran W. J. Jr., Scott C. B., Horton J., Nelson J. S., Weinstein A. S., Fischbach A. J., Chang C. H., Rotman M., Asbell S. O., Krisch R. E., Nelson D. F., Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials Journal of the National Cancer Institute 1993 85 9 704 710 (Pubitemid 23133591)
6. Prados M. D., Seiferheld W., Sandler H. M., Buckner J. C., Phillips T., Schultz C., Urtasun R., Davis R., Gutin P., Cascino T. L., Greenberg H. S., Curran W. J., Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404 International Journal of Radiation Oncology Biology Physics 2004 58 4 1147 1152 (Pubitemid 38314798)
7. Wong E. T., Hess K. R., Gleason M. J., Jaeckle K. A., Kyritsis A. P., Prados M. D., Levin V. A., Yung W. K. A., Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials Journal of Clinical Oncology 1999 17 8 2572 2578 (Pubitemid 29368260)
8. Louis D. N., Ohgaki H., Wiestler O. D., Cavenee W. K., WHO Classification of Tumours of the Central Nervous System 2007 4th Lyon, France IARC Press
9. Reijneveld J. C., Voest E. E., Taphoorn M. J. B., Angiogenesis in malignant primary and metastatic brain tumors Journal of Neurology 2000 247 8 597 608
10. Ferrara N., Gerber H. P., LeCouter J., The biology of VEGF and its receptors Nature Medicine 2003 9 6 669 676 (Pubitemid 36749215)
11. Vredenburgh J. J., Desjardins A., Herndon J. E., Marcello J., Reardon D. A., Quinn J. A., Rich J. N., Sathornsumetee S., Gururangan S., Sampson J., Wagner M., Bailey L., Bigner D. D., Friedman A. H., Friedman H. S., Bevacizumab plus irinotecan in recurrent glioblastoma multiforme Journal of Clinical Oncology 2007 25 30 4722 4729 (Pubitemid 350086473)
12. Friedman H. S., Prados M. D., Wen P. Y., Mikkelsen T., Schiff D., Abrey L. E., Yung W. K. A., Paleologos N., Nicholas M. K., Jensen R., Vredenburgh J., Huang J., Zheng M., Cloughesy T., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma Journal of Clinical Oncology 2009 27 28 4733 4740
13. Kreisl T. N., Kim L., Moore K., Duic P., Royce C., Stroud I., Garren N., Mackey M., Butman J. A., Camphausen K., Park J., Albert P. S., Fine H. A., Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma Journal of Clinical Oncology 2009 27 5 740 745
14. Lai A., Tran A., Nghiemphu P. L., Pope W. B., Solis O. E., Selch M., Filka E., Yong W. H., Mischel P. S., Liau L. M., Phuphanich S., Black K., Peak S., Green R. M., Spier C. E., Kolevska T., Polikoff J., Fehrenbacher L., Elashoff R., Cloughesy T., Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme Journal of Clinical Oncology 2011 29 2 142 148
15. Vredenburgh J. J., Desjardins A., Kirkpatrick J. P., Reardon D. A., Peters K. B., Herndon J. E., Marcello J., Bailey L., Threatt S., Sampson J., Friedman A., Friedman H. S., Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics. In press
16. Ahluwalia M. S., Gladson C. L., Progress on antiangiogenic therapy for patients with malignant glioma Journal of Oncology 2010 2010 14
17. Plate K. H., Breier G., Weich H. A., Risau W., Vascular endothelial growth factor is a potential tumour angiogenssis factor in human gliomas in vivo Nature 1992 359 6398 845 848
18. Millauer B., Shawver L. K., Plate K. H., Risau W., Ullrich A., Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant Nature 1994 367 6463 576 578 (Pubitemid 24055519)
19. Zhou Y. H., Tan F., Hess K. R., Yung W. K. A., The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival Clinical Cancer Research 2003 9 9 3369 3375 (Pubitemid 37082732)
20. Chaudhry I. H., O'Donovan D. G., Brenchley P. E. C., Reid H., Roberts I. S. D., Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas Histopathology 2001 39 4 409 415 (Pubitemid 32990094)
21. Stefanik D. F., Fellows W. K., Rizkalla L. R., Rizkalla W. M., Stefanik P. P., Deleo A. B., Welch W. C., Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograt Journal of Neuro-Oncology 2001 55 2 91 100 (Pubitemid 34065325)
22. Bao S., Wu Q., Sathornsumetee S., Hao Y., Li Z., Hjelmeland A. B., Shi Q., McLendon R. E., Bigner D. D., Rich J. N., Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor Cancer Research 2006 66 16 7843 7848 (Pubitemid 44299144)
23. Winkler F., Kozin S. V., Tong R. T., Chae S. S., Booth M. F., Garkavtsev I., Xu L., Hicklin D. J., Fukumura D., Di Tomaso E., Munn L. L., Jain R. K., Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 2004 6 6 553 563 (Pubitemid 40017699)
24. Carmeliet P., Jain R. K., Angiogenesis in cancer and other diseases Nature 2000 407 6801 249 257
25. Ferrara N., Hillan K. J., Gerber H. P., Novotny W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery 2004 3 5 391 400 (Pubitemid 38618122)
26. Presta L. G., Chen H., O'Connor S. J., Chisholm V., Meng Y. G., Krummen L., Winkler M., Ferrara N., Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Research 1997 57 20 4593 4599 (Pubitemid 27441066)
27. Kazazi-Hyseni F., Beijnen J. H., Schellens J. H. M., Bevacizumab Oncologist 2010 15 8 819 825
28. Vredenburgh J. J., Desjardins A., Herndon J. E., Dowell J. M., Reardon D. A., Quinn J. A., Rich J. N., Sathornsumetee S., Gururangan S., Wagner M., Bigner D. D., Friedman A. H., Friedman H. S., Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clinical Cancer Research 2007 13 4 1253 1259 (Pubitemid 46424067)
29. Desjardins A., Reardon D. A., Herndon J. E., Marcello J., Quinn J. A., Rich J. N., Sathornsumetee S., Gururangan S., Sampson J., Bailey L., Bigner D. D., Friedman A. H., Friedman H. S., Vredenburgh J. J., Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas Clinical Cancer Research 2008 14 21 7068 7073
30. Gutin P. H., Iwamoto F. M., Beal K., Mohile N. A., Karimi S., Hou B. L., Lymberis S., Yamada Y., Chang J., Abrey L. E., Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas International Journal of Radiation Oncology Biology Physics 2009 75 1 156 163
31. Cuneo K. C., Vredenburgh J. J., Sampson J. H., Reardon D. A., Desjardins A., Peters K. B., Friedman H. S., Willett C. G., Kirkpatrick J. P., Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. International Journal of Radiation Oncology, Biology, Physics. In press
32. Sathornsumetee S., Desjardins A., Vredenburgh J. J., McLendon R. E., Marcello J., Herndon J. E., Mathe A., Hamilton M., Rich J. N., Norfleet J. A., Gururangan S., Friedman H. S., Reardon D. A., Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma Neuro-Oncology 2010 12 12 1300 1310
33. Ahluwalia M. S., 2010 Society for neuro-oncology annual meeting: a report of selected studies Expert Review of Anticancer Therapy 2011 11 2 161 163
34. Gressett S. M., Shah S. R., Intricacies of bevacizumab-induced toxicities and their management Annals of Pharmacotherapy 2009 43 3 490 501
35. Semrad T. J., O'Donnell R., Wun T., Chew H., Harvey D., Zhou H., White R. H., Epidemiology of venous thromboembolism in 9489 patients with malignant glioma Journal of Neurosurgery 2007 106 4 601 608 (Pubitemid 46536455)
36. Ranpura V., Hapani S., Wu S., Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis JAMAJournal of the American Medical Association 2011 305 5 487 494
37. Buckner J. C., Factors influencing survival in high-grade gliomas Seminars in Oncology 2003 30 6 10 14 (Pubitemid 38199157)
38. Ananthnarayan S., Bahng J., Roring J., Nghiemphu P., Lai A., Cloughesy T., Pope W. B., Time course of imaging changes of GBM during extended bevacizumab treatment Journal of Neuro-Oncology 2008 88 3 339 347
39. Quant E. C., Norden A. D., Drappatz J., Muzikansky A., Doherty L., LaFrankie D., Ciampa A., Kesari S., Wen P. Y., Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab Neuro-Oncology 2009 11 5 550 555
40. de Groot J. F., Fuller G., Kumar A. J., Piao Y., Eterovic K., Ji Y., Conrad C. A., Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice Neuro-Oncology 2010 12 3 233 242
41. Bergers G., Hanahan D., Modes of resistance to anti-angiogenic therapy Nature Reviews Cancer 2008 8 8 592 603
42. Ebos J. M. L., Lee C. R., Kerbel R. S., Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy Clinical Cancer Research 2009 15 16 5020 5025
43. Macdonald D. R., Cascino T. L., Schold S. C., Cairncross J. G., Response criteria for phase II studies of supratentorial malignant glioma Journal of Clinical Oncology 1990 8 7 1277 1280 (Pubitemid 20195640)
44. Chi A. S., Norden A. D., Wen P. Y., Antiangiogenic strategies for treatment of malignant gliomas Neurotherapeutics 2009 6 3 513 526
45. Norden A. D., Young G. S., Setayesh K., Muzikansky A., Klufas R., Ross G. L., Ciampa A. S., Ebbeling L. G., Levy B., Drappatz J., Kesari S., Wen P. Y., Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 2008 70 10 779 787
46. Iwamoto F. M., Abrey L. E., Beal K., Gutin P. H., Rosenblum M. K., Reuter V. E., Deangelis L. M., Lassman A. B., Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma Neurology 2009 73 15 1200 1206
47. Wen P. Y., Macdonald D. R., Reardon D. A., Cloughesy T. F., Sorensen A. G., Galanis E., Degroot J., Wick W., Gilbert M. R., Lassman A. B., Tsien C., Mikkelsen T., Wong E. T., Chamberlain M. C., Stupp R., Lamborn K. R., Vogelbaum M. A., van den Bent M. J., Chang S. M., Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group Journal of Clinical Oncology 2010 28 11 1963 1972
48. Barwick T., Bencherif B., Mountz J. M., Avril N., Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation Nuclear Medicine Communications 2009 30 12 908 917
49. Chen W., Delaloye S., Silverman D. H. S., Geist C., Czernin J., Sayre J., Satyamurthy N., Pope W., Lai A., Phelps M. E., Cloughesy T., Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study Journal of Clinical Oncology 2007 25 30 4714 4721 (Pubitemid 350086472)
50. Ellingson B. M., Cloughesy T. F., Lai A., Nghiemphu P. L., Mischel P. S., Pope W. B., Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab Neuro-Oncology 2011 13 4 401 409
51. Jubb A. M., Harris A. L., Biomarkers to predict the clinical efficacy of bevacizumab in cancer The Lancet Oncology 2010 11 12 1172 1183
52. Sathornsumetee S., Cao Y., Marcello J. E., Herndon J. E., McLendon R. E., Desjardins A., Friedman H. S., Dewhirst M. W., Vredenburgh J. J., Rich J. N., Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan Journal of Clinical Oncology 2008 26 2 271 278
53. Pau E. C. D. S., Arias F. C., Pelaez E. C., Trueba I. M., Hernndez I. S., Molina G. M. M., Balsalobre R. M., Lpez S. S., Gmez-Pinillos A., Toledo Lobo M. D. V., Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients Cancer Investigation 2010 28 4 393 398
54. Gururangan S., Chi S. N., Young Poussaint T., Onar-Thomas A., Gilbertson R. J., Vajapeyam S., Friedman H. S., Packer R. J., Rood B. N., Boyett J. M., Kun L. E., Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study Journal of Clinical Oncology 2010 28 18 3069 3075
55. Sargent D. J., Conley B. A., Allegra C., Collette L., Clinical trial designs for predictive marker validation in cancer treatment trials Journal of Clinical Oncology 2005 23 9 2020 2027 (Pubitemid 46211382)
56. http://clinicaltrials.gov/ct2/show/NCT00884741?term=rtog+0825rank=1
57. http://www.isesd.cv.ic.ac.uk
58. Sherman J. H., Aregawi D. G., Lai A., Fathallah-Shaykh H. M., Bierman P. J., Linsky K., Larner J. M., Newman S. A., Schiff D., Optic neuropathy in patients with glioblastoma receiving bevacizumab Neurology 2009 73 22 1924 1926
59. Kelly P. J., Dinkin M. J., Drappatz J., O'Regan K. N., Weiss S. E., Unexpected late radiation neurotoxicity following bevacizumab use: a case series Journal of Neuro-Oncology 2010 102 3 485 490
60. Gonzalez J., Kumar A. J., Conrad C. A., Levin V. A., Effect of bevacizumab on radiation necrosis of the brain International Journal of Radiation Oncology Biology Physics 2007 67 2 323 326 (Pubitemid 46108339)
61. Giuliari G. P., Sadaka A., Hinkle D. M., Simpson E. R., Current treatments for radiation retinopathy Acta Oncologica 2011 50 1 6 13
62. Crossen J. R., Garwood D., Glatstein E., Neuwelt E. A., Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy Journal of Clinical Oncology 1994 12 3 627 642 (Pubitemid 24079908)
63. Li Y. Q., Ballinger J. R., Nordal R. A., Su Z. F., Wong C. S., Hypoxia in radiation-induced blood-spinal cord barrier breakdown Cancer Research 2001 61 8 3348 3354 (Pubitemid 32695024)
64. Giglio P., Gilbert M. R., Cerebral radiation necrosis Neurologist 2003 9 4 180 188 (Pubitemid 36944725)
65. Wong E. T., Huberman M., Lu X. Q., Mahadevan A., Bevacizumab reverses cerebral radiation necrosis Journal of Clinical Oncology 2008 26 34 5649 5650
66. Torcuator R., Zuniga R., Mohan Y. S., Rock J., Doyle T., Anderson J., Gutierrez J., Ryu S., Jain R., Rosenblum M., Mikkelsen T., Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis Journal of Neuro-Oncology 2009 94 1 63 68
67. Furuse M., Kawabata S., Kuroiwa T., Miyatake S. I., Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases Journal of Neuro-Oncology 2010 1 5
68. Levin V. A., Bidaut L., Hou P., Kumar A. J., Wefel J. S., Bekele B. N., Prabhu S., Loghin M., Gilbert M. R., Jackson E. F., Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system International Journal of Radiation Oncology, Biology, Physics 2010 79 5 1487 1495
69. Finger P. T., Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin) International Journal of Radiation Oncology Biology Physics 2008 70 4 974 977 (Pubitemid 351296131)
70. Finger P. T., Chin K. J., Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy. International Journal of Radiation Oncology, Biology, Physics. In press
71. Jeyaretna D. S., Curry Jr. W. T., Batchelor T. T., Stemmer-Rachamimov A., Plotkin S. R., Exacerbation of cerebral radiation necrosis by bevacizumab Journal of Clinical Oncology 2011 29 7 e159 e162
72. Beal K., Abrey L. E., Gutin P. H., Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches Radiation Oncology 2011 6, article 2
73. Reardon D. A., Fink K. L., Mikkelsen T., Cloughesy T. F., O'Neill A., Plotkin S., Glantz M., Ravin P., Raizer J. J., Rich K. M., Schiff D., Shapiro W. R., Burdette-Radoux S., Dropcho E. J., Wittemer S. M., Nippgen J., Picard M., Nabors L. B., Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme Journal of Clinical Oncology 2008 26 34 5610 5617
74. Stupp R., Hegi M. E., Neyns B., Goldbrunner R., Schlegel U., Clement P. M., Grabenbauer G. G., Ochsenbein A. F., Simon M., Dietrich P. Y., Pietsch T., Hicking C., Tonn J. C., Diserens A. C., Pica A., Hermisson M., Krueger S., Picard M., Weller M., Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma Journal of Clinical Oncology 2010 28 16 2712 2718
75. Fine H. A., Figg W. D., Jaeckle K., Wen P. Y., Kyritsis A. P., Loeffler J. S., Levin V. A., Black P. M., Kaplan R., Pluda J. M., Yung W. K. A., Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas Journal of Clinical Oncology 2000 18 4 708 715 (Pubitemid 30106600)
76. Fine H. A., Wen P. Y., Maher E. A., Viscosi E., Batchelor T., Lakhani N., Figg W. D., Purow B. W., Borkowf C. B., Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas Journal of Clinical Oncology 2003 21 12 2299 2304 (Pubitemid 46621867)
77. Puduvalli V. K., Giglio P., Groves M. D., Hess K. R., Gilbert M. R., Mahankali S., Jackson E. F., Levin V. A., Conrad C. A., Hsu S. H., Colman H., De Groot J. F., Ritterhouse M. G., Ictech S. E., Yung W. K. A., Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neuro-Oncology 2008 10 2 216 222
78. Fine H. A., Kim L., Albert P. S., Duic J. P., Ma H., Tohnya T., Figg W. D., Royce C., A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors Clinical Cancer Research 2007 13 23 7101 7106 (Pubitemid 350276894)
79. Batchelor T. T., Duda D. G., Di Tomaso E., Ancukiewicz M., Plotkin S. R., Gerstner E., Eichler A. F., Drappatz J., Hochberg F. H., Benner T., Louis D. N., Cohen K. S., Chea H., Exarhopoulos A., Loeffler J. S., Moses M. A., Ivy P., Sorensen A. G., Wen P. Y., Jain R. K., Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma Journal of Clinical Oncology 2010 28 17 2817 2823
80. Hainsworth J. D., Ervin T., Friedman E., Priego V., Murphy P. B., Clark B. L., Lamar R. E., Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme Cancer 2010 116 15 3663 3669
81. Neyns B., Sadones J., Chaskis C., Dujardin M., Everaert H., Lv S., Duerinck J., Tynninen O., Nupponen N., Michotte A., De Greve J., Phase II study of sunitinib malate in patients with recurrent high-grade glioma Journal of Neuro-Oncology 2010 1 11
82. Gerstner E. R., Eichler A. F., Plotkin S. R., Drappatz J., Doyle C. L., Xu L., Duda D. G., Wen P. Y., Jain R. K., Batchelor T. T., Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide Journal of Neuro-Oncology 2010 103 2 325 332
83. Iwamoto F. M., Lamborn K. R., Robins H. I., Mehta M. P., Chang S. M., Butowski N. A., DeAngelis L. M., Abrey L. E., Zhang W. T., Prados M. D., Fine H. A., Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02) Neuro-Oncology 2010 12 8 855 861
84. Raymond E., Brandes A. A., Dittrich C., Fumoleau P., Coudert B., Clement P. M. J., Frenay M., Rampling R., Stupp R., Kros J. M., Heinrich M. C., Gorlia T., Lacombe D., Van Den Bent M. J., Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European organisation for research and treatment of cancer brain tumor group study Journal of Clinical Oncology 2008 26 28 4659 4665
85. Dresemann G., Weller M., Rosenthal M. A., Wedding U., Wagner W., Engel E., Heinrich B., Mayer-Steinacker R., Karup-Hansen A., Fluge E., Nowak A., Mehdorn M., Schleyer E., Krex D., Olver I. N., Steinbach J. P., Hosius C., Sieder C., Sorenson G., Parker R., Nikolova Z., Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide Journal of Neuro-Oncology 2010 96 3 393 402
86. Lu-Emerson C., Norden A. D., Drappatz J., Quant E. C., Beroukhim R., Ciampa A. S., Doherty L. M., LaFrankie D. C., Ruland S., Wen P. Y., Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. Journal of Neuro-Oncology. In press
87. Maurer G. D., Tritschler I., Adams B., Tabatabai G., Wick W., Stupp R., Weller M., Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro Neuro-Oncology 2009 11 6 747 756
88. Nisato R. E., Tille J. C., Jonczyk A., Goodman S. L., Pepper M. S., v 3 and v 5 integrin antagonists inhibit angiogenesis in vitro Angiogenesis 2003 6 2 105 119 (Pubitemid 38173862)
89. Schnell O., Krebs B., Wagner E., Romagna A., Beer A. J., Grau S. J., Thon N., Goetz C., Kretzschmar H. A., Tonn J. C., Goldbrunner R. H., Expression of integrin v 3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature Brain Pathology 2008 18 3 378 386 (Pubitemid 351782847)
90. Yamada S., Bu X. Y., Khankaldyyan V., Gonzales-Gomez I., McComb J. G., Laug W. E., Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice Neurosurgery 2006 59 6 1304 1312 (Pubitemid 44949775)
91. Stupp R., van den Bent M., Erridge S., Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC) Journal of Clinical Oncology 2010 28 15. abstract TPS152
92. Nabors L., Fink K., Reardon D., Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: protocol of a multicenter, randomized, open-label, controlled phase II study Journal of Clinical Oncology 2010 28 15. abstract TPS151
93. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J., Thalidomide is an inhibitor of angiogenesis Proceedings of the National Academy of Sciences of the United States of America 1994 91 9 4082 4085 (Pubitemid 24139577)
94. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeldis J., Barlogie B., Siegel D., Crowley J., Antitumor activity of thalidomide in refractory multiple myeloma The New England Journal of Medicine 1999 341 21 1565 1571
95. Dredge K., Horsfall R., Robinson S. P., Zhang L. H., Lu L., Tang Y., Shirley M. A., Muller G., Schafer P., Stirling D., Dalgleish A. G., Bartlett J. B., Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Microvascular Research 2005 69 1-2 56 63 (Pubitemid 40410468)
96. Zhu D., Corral L. G., Fleming Y. W., Stein B., Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation Cancer Immunology, Immunotherapy 2008 57 12 1849 1859
97. Warren K. E., Goldman S., Pollack I. F., Fangusaro J., Schaiquevich P., Stewart C. F., Wallace D., Blaney S. M., Packer R., MacDonald T., Jakacki R., Boyett J. M., Kun L. E., Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: pediatric Brain Tumor Consortium Study PBTC-018 Journal of Clinical Oncology 2011 29 3 324 329
98. Batchelor T. T., Sorensen A. G., di Tomaso E., AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 2007 11 1 83 95 (Pubitemid 46075199)
99. Kamoun W. S., Ley C. D., Farrar C. T., Duyverman A. M., Lahdenranta J., Lacorre D. A., Batchelor T. T., Di Tomaso E., Duda D. G., Munn L. L., Fukumura D., Gregory Sorensen A., Jain R. K., Edema control by cediranib, a vascular endothelial growth factor receptortargeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice Journal of Clinical Oncology 2009 27 15 2542 2552
100. Iyer R., Fetterly G., Lugade A., Thanavala Y., Sorafenib: a clinical and pharmacologic review Expert Opinion on Pharmacotherapy 2010 11 11 1945 1955
101. Scott B. J., Quant E. C., McNamara M. B., Ryg P. A., Batchelor T. T., Wen P. Y., Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors Neuro-Oncology 2010 12 6 603 607
102. Wong E. T., Brem S., Taming glioblastoma by targeting angiogenesis: 3 Yyears later Journal of Clinical Oncology 2011 29 2 124 126
103. Laird A. D., Vajkoczy P., Shawver L. K., Thurnher A., Liang C., Mohammadi M., Schlessinger J., Ullrich A., Hubbard S. R., Blake R. A., Fong T. A. T., Strawn L. M., Sun L., Tang C., Hawtin R., Tang F., Shenoy N., Hirth K. P., McMahon G., Cherrington J. M., SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors Cancer Research 2000 60 15 4152 4160 (Pubitemid 30636598)
104. Hgerstrand D., Hesselager G., Achterberg S., Wickenberg Bolin U., Kowanetz M., Kastemar M., Heldin C. H., Isaksson A., Nistér M., stman A., Characterization of an imatinib-sensitive subset of high-grade human glioma cultures Oncogene 2006 25 35 4913 4922 (Pubitemid 44201182)
105. Talpaz M., Shah N. P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., Blackwood-Chirchir M. A., Iyer V., Chen T. T., Huang F., Decillis A. P., Sawyers C. L., Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias The New England Journal of Medicine 2006 354 24 2531 2541 (Pubitemid 43882349)
106. http://clinicaltrials.gov/ct2/show/NCT00423735?term=RTOG+0627rank=1
107. Lehky T. J., Iwamoto F. M., Kreisl T. N., Floeter M. K., Fine H. A., Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome Neurology 2011 76 3 236 241
108. Dai H., Marbach P., Lemaire M., Hayes M., Elmquist W. F., Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux Journal of Pharmacology and Experimental Therapeutics 2003 304 3 1085 1092 (Pubitemid 36254421)
109. Cannistra S. A., Phase II trials in journal of clinical oncology Journal of Clinical Oncology 2009 27 19 3073 3076